Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Milrinone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A known ✓ | Q14432 | 8/20 | 0.79 |
| ▸ | PDE3B | Q13370 | 7/20 | 0.79 |
| ▸ | HPGD | P15428 | 3/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.79 |
| ▸ | PDE4A | P27815 | 3/20 | 0.79 |
| ▸ | BLM | P54132 | 2/20 | 0.79 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.79 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.79 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.79 |
| ▸ | PDE5A | O76074 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
| ▸ | GALR3 | O60755 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | PDE2A | O00408 | 1/20 | 0.57 |
| ▸ | PDE1A | P54750 | 1/20 | 0.57 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Milrinone SCHEMBL3463564 | 1.00 | PDE3A (0.79) | PDE3APDE3BHPGDKDM4EPDE4A | |
| Milrinone SCHEMBL36948 | 0.91 | PDE3A (0.75) | PDE3APDE3BHPGDKDM4EPDE4A | |
| Milrinone SCHEMBL36947 | 0.89 | PDE3A (1.00) | PDE3APDE3BHPGDKDM4EPDE4A | |
| Milrinone SCHEMBL9309054 | 0.89 | PDE3A (1.00) | PDE3APDE3BHPGDKDM4EPDE4A | |
| Milrinone SCHEMBL9301167 | 0.89 | PDE3A (1.00) | PDE3APDE3BHPGDKDM4EPDE4A | |
| Milrinone SCHEMBL9247989 | 0.89 | PDE3A (1.00) | PDE3APDE3BHPGDKDM4EPDE4A | |
| Milrinone SCHEMBL28184205 | 0.87 | PDE3A (0.97) | PDE3APDE3BHPGDKDM4EPDE4A | |
| Milrinone SCHEMBL1160021 | 0.86 | PDE3A (0.94) | PDE3APDE3BHPGDKDM4EPDE4A | |
| Milrinone SCHEMBL9132559 | 0.86 | PDE3A (0.94) | PDE3APDE3BHPGDKDM4EPDE4A | |
| Milrinone SCHEMBL8578994 | 0.86 | PDE3A (0.79) | PDE3APDE3BHPGDKDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1012 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20220211645-A1 | Maximizing Distribution and Minimizing Washout of Injectates in Bone and Method for Enhanced Aspirate Extraction | YALE UNIVERSITY | 2022-07-07 | — | — | US | claimed |
| EP-3965635-A2 | MAXIMIZING DISTRIBUTION AND MINIMIZING WASHOUT OF INJECTATES IN BONE AND METHOD FOR ENHANCED ASPIRATE EXTRACTION | Yale University (US) | 2022-03-16 | — | — | EP | claimed |
| WO-2020227558-A2 | MAXIMIZING DISTRIBUTION AND MINIMIZING WASHOUT OF INJECTATES IN BONE AND METHOD FOR ENHANCED ASPIRATE EXTRACTION | YALE UNIVERSITY (US) | 2020-11-12 | — | — | WO | claimed |
| US-10799599-B2 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | CYDEX PHARMACEUTICALS, INC. (US) | 2020-10-13 | — | — | US | claimed |
| US-10703826-B2 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CYDEX PHARMACEUTICALS, INC. (US) | 2020-07-07 | — | — | US | claimed |
| US-20190105404-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-04-11 | — | — | US | claimed |
| CN-106361710-B | A kind of milrinone lactate composition | 海南合瑞制药股份有限公司 | 2019-03-05 | — | — | CN | claimed |
| US-10207008-B2 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | CYDEX PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | claimed |
| US-10159752-B2 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | CYDEX PHARMACEUTICALS, INC. (US) | 2018-12-25 | — | — | US | claimed |
| US-20020183293-A1 | Administering durg comprising formoterol, or a derivative thereof and asteroidal anti-inflammatory agent, or a derivative in a pharmacologically suitable fluid, wherein the drug formulation is stable during long term storage | MYLAN PHARMACEUTICALS, INC. | 2002-12-05 | — | — | US | claimed |
| WO-2002083113-A2 | AEROSOL COMPOSITIONS CONTAINING FORMOTEROL AND A STEROID SUCH AS E.G. BUDESONIDE OR FLUTICASONE FOR DELIVERY INTO THE LUNGS VIA NEBULIZATION | DEY, L.P. (US) | 2002-10-24 | — | — | WO | claimed |
| WO-2002083079-A2 | AEROSOL COMPOSITIONS CONTAINING FORMOTEROL FOR DELIVERY TO THE LUNGS VIA NEBULIZATION | DEY, L.P. (US) | 2002-10-24 | — | — | WO | claimed |
| US-20020151598-A1 | Formoterol, or a derivative; long term storage stability | MYLAN TECHNOLOGIES, INC. | 2002-10-17 | — | — | US | claimed |
| US-20020151597-A1 | Formoterol, or a derivative; long term storage stability | DEY L.P. | 2002-10-17 | — | — | US | claimed |
| WO-2002026318-A1 | METHOD AND SYSTEM FOR NERVE STIMULATION AND CARDIAC SENSING PRIOR TO AND DURING A MEDICAL PROCEDURE | MEDTRONIC, INC. (US) | 2002-04-04 | — | — | WO | claimed |
| EP-1176960-A1 | SYNERGISTIC COMBINATION COMPRISING ROFLUMILAST AND A PDE-3 INHIBITOR | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2002-02-06 | — | — | EP | claimed |
| US-20020003179-A1 | Media milling | SKYEPHARMA AG (CH) | 2002-01-10 | — | — | US | claimed |
| WO-2001085345-A1 | MEDIA MILLING | RTP PHARMA INC. (US) | 2001-11-15 | — | — | WO | claimed |
| WO-2000066123-A1 | SYNERGISTIC COMBINATION COMPRISING ROFLUMILAST AND A PDE-3 INHIBITOR | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-11-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10799599-B2 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | STS, SAE1, PDCD2L | PDE3A 2441/4885PDE3B 2500/4885HPGD 2612/4885 |
| US-20020151597-A1 | Formoterol, or a derivative; long term storage stability | ADRB2, ADRA2C, ADRA2A | PDE3A 19/4885PDE3B 43/4885HPGD 199/4885 |
| US-20190105404-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | STS, SAE1, PDCD2L | PDE3A 2441/4885PDE3B 2500/4885HPGD 2612/4885 |
| US-10207008-B2 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | STS, SAE1, PDCD2L | PDE3A 2441/4885PDE3B 2500/4885HPGD 2612/4885 |
| US-20020183293-A1 | Administering durg comprising formoterol, or a derivative thereof and asteroidal anti-inflammatory agent, or a derivative in a pharmacologically suitable fluid, wherein the drug formulation is stable during long term storage | AREG, IL5, IL17A | PDE3A 96/4885PDE3B 101/4885HPGD 134/4885 |
| US-20020151598-A1 | Formoterol, or a derivative; long term storage stability | ADRB2, ADRA2C, ADRA2A | PDE3A 19/4885PDE3B 43/4885HPGD 199/4885 |
| US-10159752-B2 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | STS, SAE1, PDCD2L | PDE3A 2441/4885PDE3B 2500/4885HPGD 2612/4885 |
| US-10703826-B2 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | SAE1, SDC4, SPECC1L | PDE3A 3304/4885PDE3B 3349/4885HPGD 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.